Introduction
============

Atopic dermatitis (AD) involves a complex immune response mediated by T helper (Th) 1 and Th2 T cell subsets ([@b1-mmr-15-02-0649]). Chronic skin lesions of AD are dominated by Th1-type cytokine responses with high levels of interferon (IFN)-γ. The Th2-type cytokines, interleukin (IL)-4, −6 and −13, serve important roles in the increase in the levels of serum immunoglobulin E (IgE) and mast cells during AD development ([@b2-mmr-15-02-0649]). Therefore, Th1 and Th2 cytokines may contribute to AD lesions ([@b3-mmr-15-02-0649]).

The topical application of steroids is typically recommended for the treatment of AD ([@b4-mmr-15-02-0649]). However, topical steroids have various well-known adverse effects, including skin atrophy, a tendency for bruising, tachyphylaxis and the rebound phenomenon ([@b5-mmr-15-02-0649]). Therefore, herbal medicines have been investigated as potential topical agents for the treatment of AD.

*Pseudostellaria heterophylla* (Miquel) Pax has been described as a type of 'qi-enriching and tonic drug' ([@b6-mmr-15-02-0649]), which has a beneficial effect for the immune system ([@b7-mmr-15-02-0649]). In addition, *Pseudostellaria heterophylla* (PH) has mild toning effects on the body, leading to its widespread use in herbal medicines and healthcare products ([@b8-mmr-15-02-0649],[@b9-mmr-15-02-0649]). The primary components of PH include polysaccharides, cycle peptides, amino acids, volatile compounds, saponins, amino acids and minerals. In particular, macromolecule polysaccharides are considered to be the primary active component of PH ([@b10-mmr-15-02-0649]). Previous studies have suggested that PH has immunomodulatory, anti-inflammatory and anti-oxidant properties ([@b7-mmr-15-02-0649],[@b11-mmr-15-02-0649]). These diverse biological activities may be beneficial for the treatment of AD.

The present study therefore aimed to evaluate the immunomodulatory activity of PH water extracts in a 2,4-dinitrochlorobenzene (DNCB)-induced mouse model of AD.

Materials and methods
=====================

### Preparation of sample

PH was supplied by Jung-do Herb Inc. (Guri, Korea) and was authenticated by Professor Woong Mo Yang (Kyung Hee University, Seoul, Korea). The crude drug (100 g) was extracted with 1,000 ml distilled water for 24 h at room temperature. Following filtration, the extracted solution was concentrated in a rotary evaporator, freeze-dried for three days, and stored in aliquots at −70°C. The yield from the dried roots was 23.09%. The authenticated voucher specimens (no. PH131201) were stored in the College of Pharmacy of Kyung Hee University. The PH extracts was dissolved in distilled water immediately prior to use.

### Animal model

A total of 25 female BALB/c mice (age, 6 weeks; weight, 18--22 g) were obtained from Raon Bio Inc. (Yongin, Korea) and housed in an air-conditioned room at a temperature of 23±1°C and relative humidity of 60±5%, under a 12-h light/dark cycle. During the experimental period, all mice received standard mouse chow and water *ad libitum*. All experiments were conducted according to the guidelines of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by Committee on Care and Use of Laboratory Animals of the Kyung Hee University (approval no. KHUASP (SE)-14-030; Seoul, Korea). Following an acclimation period of 1 week, mice were randomly divided into five groups (n=5): NOR, in which mice were challenged with vehicle treatment as a baseline control; DNCB, in which mice were sensitized with 100 µl/day 1 or 0.5% DNCB (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) as negative control; DEX, in which mice were topically treated with 100 µl/day 10 µM dexamethasone (DEX; Sigma-Aldrich; Merck Millipore) following DNCB sensitization as positive control; PH1, in which mice were topically treated with 100 µl/day 1 mg/ml PH following DNCB sensitization; and PH100, in which mice were topically treated with 100 µl/day 100 mg/ml PH following DNCB sensitization.

To induce dermatitis, 100 µl 1% DNCB solution \[in acetone: olive oil at a ratio of 4:1 (v/v)\] was applied onto the shaved dorsal skin of all mice excluding the NOR group once a day for 3 days (day 1--3). Following the first challenge, mice were left untreated for 4 days (day 4--7). In the second challenge, PH (1 or 100 mg/ml) or DEX was topically applied to mice prior to the application of 0.5% DNCB for 11 consecutive days (day 8 to day 18). An equal volume of vehicle was applied to the NOR group at the same time points. All animals were sacrificed 24 h after the last treatment (day 19) under anesthesia with intraperitoneal injection of a tiletamine/zolazepam mixture (30 mg/kg, Zoletil 50; Virbac Lab, Carros, France). Serum was collected by cardiac puncture and the dorsal skin of mice was biopsied for histopathology and measurement of tissue cytokines levels.

### Histopathology

To evaluate skin thickening and mast cell infiltration, the dorsal skin samples (1×0.4 cm^2^) were prepared at sacrifice (day 19). Samples were fixed in 10% buffered formalin (Sigma-Aldrich; Merck Millipore), embedded in paraffin and cut into 4-µm thick sections. Following dewaxing and dehydration of paraffin sections, hematoxylin and eosin staining was performed to assess skin thickening and toluidine blue staining to detect mast cells as previously described ([@b12-mmr-15-02-0649]). Histopathological alterations were examined using the Leica Application Suite (LAS; Leica Microsystems, Inc., Buffalo Grove, IL, USA) and viewed at magnification, ×100. Skin thickness was measured in \>5 fields, at intervals of 200 µm, in each sample (n=5). The number of mast cells was measured in the entire area of each section (19.05×25.4 cm) for each sample (n=5).

### IgE concentrations in plasma, as detected by ELISA

Blood was allowed to clot for 30 min at room temperature. The serum was prepared by centrifugation (10,000 × g for 10 min at room temperature) and stored at −70°C until use. The concentrations of IgE in serum were determined using a Mouse IgE ELISA kit (cat. no. 555248; BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer\'s protocol.

### Cluster of differentiation (CD)4^+^ cell expression, as detected by immunohistochemistry (IHC)

IHC was performed according to the manufacturer\'s protocol. To retrieve antigens in the skin tissues, the deparaffinized sections were boiled in 10 mM sodium citrate buffer for 30 min. Endogenous peroxidase was subsequently blocked by incubation in 3% H~2~O~2~ for 30 min and slides were blocked with 5% normal goat serum (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) in phosphate-buffered saline (PBS) containing 5% fetal bovine serum (Corning, Inc., Corning, NY, USA), 2% bovine serum albumin (BSA; Vector Laboratories, Burlingame, CA, USA) and 0.1% Triton X-100 for 1 h. Following washing in PBS three times, the sections were incubated overnight with an antibody against biotin anti-mouse CD4 (cat. no. 100403; BioLegend, Inc., San Diego, CA, USA), diluted 1:100 in normal goat serum, in a humidified chamber. After washing with PBS, the biotinylated goat anti-mouse IgG (cat. no. BA-9200; diluted 1:200 in TBST; Vector Laboratories) was applied for 2 h at room temperature. The slides were subsequently incubated with an Avidin/Biotinylated Enzyme Complex kit (Vector Laboratories) for 1 h, followed by the substrate chromogen (3,3-diaminobenzidine; Dako, Glostrup, Denmark), and counterstained by hematoxylin staining. CD4 staining was visualized using LAS (magnification, ×200).

### RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR)

To detect mRNA expression levels of various inflammatory cytokines, RT-PCR was performed. Total RNA was extracted from excised dorsal skin using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s protocol, and quantified by determining the optical density at a wavelength of 260 nm. Isolated total RNA (1 µg) was used as a template for cDNA synthesis. RT was performed using a cDNA Synthesis kit (Invitrogen) at 45°C for 1 h. The reaction was terminated by incubation at 95°C for 5 min, and cDNA was stored at −20°C. PCR was performed using the synthesized cDNA as a template and Maxime PCR premix kit (Invitrogen; Thermo Fisher Scientific, Inc.) and specific primers for mouse IFN-γ, IL-4, IL-6, IL-8, tumor necrosis factor (TNF)-α, IL-1β and GAPDH. Cycling conditions were as follows: Initial denaturation cycle for 5 min at 94°C, 30 cycles of amplification for 2 min at 72°C, 1 min at 94°C, 1 min at 60°C, and a final extension phase consisting of 1 cycle of 10 min at 72°C. The primers were designed using Primer Express software version 3.0 (Applied Biosystems; Thermo Fisher Scientific, Inc.) and the sequences of primers are presented in [Table I](#tI-mmr-15-02-0649){ref-type="table"}. Amplicons were visualized on 2% agarose gel stained with ethidium bromide using a GDS-200D Gel Image System version PSRem164 (UVP, Inc., CA, USA). All mRNA levels were normalized to the housekeeping gene GAPDH by a computerized densitometry system (ImageJ version 1.38e; National Institutes of Health, Bethesda, MD, USA).

### Analysis of inflammatory protein expression by western blot analysis

To determine the mechanisms underlying the development of AD-like skin lesions, the protein expression levels of the pro-inflammatory mediators, such as nuclear factor (NF)-κB, phosphorylated (p)-inhibitor of (I)κBα and p-mitogen-activated protein kinases (MAPKs) were examined in skin homogenates. To detect p-IκBα the dorsal skin samples were homogenized by the addition of the cytoplasmic buffer \[10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) at pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM ethylene glycol-bis (β-aminoethyl ether)-N,N,N\',N\'-tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT), 0.15% Nonidet P-40, 50 mM β-glycerophosphate, 10 mM NaF and 5 mM Na~3~VO~4~\] containing protease inhibitors. The cytoplasmic protein extracts were collected following sample centrifugation at 10,000 × g for 30 min at 4°C. Cytoplasmic proteins were collected from the supernatant, and nuclear lysis buffer (20 mM HEPES at pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.50% Nonidet P-40, 50 mM β-glycerophosphate, 10 mM NaF and 5 mM Na~3~VO~4~) was added to the pellet, homogenized on ice for 20 min, and centrifuged at 16,000 × g for 30 min at 4°C. The resultant homogenate was carefully removed without disturbing the pellet for assay of activated NF-κB. The protein expression levels of the MAPKs extracellular signal-regulated kinase (ERK) 1/2, c-Jun N-terminal kinase (JNK) and p38 were confirmed in whole extracts using radioimmunoprecipitation assay buffer containing a protease inhibitor cocktail. The cytoplasmic, nuclear and whole protein extracts were subsequently used for western blotting. Proteins were quantified by the bicinchoninic acid method according to the manufacturer\'s protocol (Pierce; Thermo Fisher Scientific, Inc.). The proteins (30 µg) were resolved in 10% SDS-PAGE gels and electroblotted onto polyvinylidene difluoride membranes. The membranes were blocked with 5% BSA for 1 h at room temperature and incubated with antibodies against β-actin (cat. no. sc-47778; Santa Cruz Biotechnology, Inc.), lamin-B (cat. no. sc-374015; Santa Cruz Biotechnology, Inc.), NF-κB (cat. no. sc-372; Santa Cruz Biotechnology, Inc.), p-IκBα (cat. no. sc-8404; Santa Cruz Biotechnology, Inc.), ERK1/2 (cat. no. 4695; Cell Signaling Technology, Inc., Danvers, MA, USA), p-ERK1/2 (cat. no. 4370; Cell Signaling, Inc.), JNK (cat. no. 9252; Cell Signaling Technology, Inc.), p-JNK (cat. no. 9251; Cell Signaling Technology, Inc.), p38 (cat. no. 9212; Cell Signaling Technology, Inc.) and p-p38 (cat. no. 4631; Cell Signaling Technology, Inc.), diluted 1:1,000 in TBS containing Tween-20 (TBST) for overnight at 4°C. Membranes were subsequently incubated with a horseradish peroxidase-conjugated secondary anti-mouse antibody (cat. no. sc-2005; Santa Cruz Biotechnology, Inc.) and anti-rabbit antibody (cat. no. sc-2004; Santa Cruz Biotechnology, Inc.) diluted 1:2,000 in TBST for 2 h at room temperature. The immunoreactive proteins were detected with an Enhanced Chemiluminescence reagent (Pierce; Thermo Fisher Scientific, Inc.). Band intensities were quantified by a computerized densitometry software ImageJ version 1.38e.

### Statistical analysis

Data are expressed as the mean ± standard deviation. Comparisons between the values for different variables were analyzed by one-way analysis of variance followed by Dunnett\'s t-test. P\<0.05 was considered to indicate a statistically significant difference using a GraphPad PRISM 5 software version 5 (GraphPad Software, Inc., La Jolla, CA, USA).

Results
=======

### PH treatment reduces dorsal skin thickness

To evaluate AD symptoms, histological analysis was performed on the dorsal skin of each group ([Fig. 1A](#f1-mmr-15-02-0649){ref-type="fig"}). Repeated DNCB-treatment caused a thickening of the epidermis and dermis (P\<0.001). Topically applied 1 and 100 mg/ml PH suppressed epidermal hyperplasia and dermal thickening, as did 10 µM DEX. Quantitative analysis revealed that the PH1, PH100 and DEX groups (P\<0.001) demonstrated a 27.4, 44.6 and 47.2% reduction in epidermal thickness ([Fig. 1B](#f1-mmr-15-02-0649){ref-type="fig"}). In addition, 12.3, 27.0 and 27.1% reduction of dermal thickness was observed in PH1 (P\<0.01), PH100 (P\<0.01) and DEX (P\<0.001; [Fig. 1C](#f1-mmr-15-02-0649){ref-type="fig"}).

### PH inhibits the infiltration of mast cells into the dermis

DNCB-treated skin lesions (P\<0.001) revealed increased infiltration of mast cells compared with the NOR group ([Fig. 2A and B](#f2-mmr-15-02-0649){ref-type="fig"}). Topical application of PH1, PH100 or DEX markedly decreased this infiltration (P\<0.001).

### PH reduces serum IgE levels

The concentration of IgE in the plasma of the NOR group was 143.4±51.49 ng/ml. This increased to 4348.0±446.05 ng/ml in the DNCB group (P\<0.001; [Fig. 2C](#f2-mmr-15-02-0649){ref-type="fig"}). The serum IgE levels in the PH1, PH100 and DEX groups was reduced \~1.4-, \~3.7- and \~2.2-fold compared with the DNCB group (P\<0.001).

### PH suppresses the infiltration of CD4^+^ cells

To examine the accumulation of CD4^+^ cells in allergic inflamed skin, the expression of CD4 in dorsal skin sections was detected by IHC ([Fig. 3](#f3-mmr-15-02-0649){ref-type="fig"}). Increased immunostaining was observed in the DNCB group compared with the NOR group. The detection of CD4 expression was markedly reduced in mice treated with PH1, PH100 or DEX compared with the DNCB group.

### PH inhibits the mRNA expression levels of Th1 and Th2 cytokines in dorsal skin lesions

To elucidate the effect of PH treatment on cytokine expression, alterations in the mRNA expression levels of various cytokines were analyzed, including Th1-specific (IFN-γ), Th2-specific (IL-4) and pro-inflammatory (IL-6, IL-8, TNF-α and IL-1β) cytokines ([Fig. 4](#f4-mmr-15-02-0649){ref-type="fig"}). The DNCB group (P\<0.001) expressed increased expression levels of Th1 and pro-inflammatory cytokine mRNA in skin tissues compared with the NOR group. PH (1 and 100 mg/ml) and DEX suppressed the Th1 and pro-inflammatory cytokine production stimulated by DNCB application. The inhibitory effects of the PH1, PH100 and DEX groups were as follows: 32.5, 51.0 and 47.7% for IFN-γ (PH1 and PH100; P\<0.001); 26.8, 36.2 and 27.5% for TNF-α (PH1, P\<0.01; PH100, P\<0.001); and 14.7, 29.8 and 44.2% for IL-1β (PH100, P\<0.001), respectively. Similarly, the mRNA expression levels of IL-4, IL-6 and IL-8 markedly increased following DNCB application compared with the NOR group (P\<0.001). PH treatment suppressed IL-4 and IL-6 mRNA expressions at all concentrations (PH1, P\<0.05; PH100, P\<0.001). In PH-treated AD legion, elevated IL-8 mRNA levels were decreased (PH1, P\<0.01; PH100, P\<0.001). In addition, DEX treatment significantly reduced the expression levels of these cytokines (P\<0.001).

### PH decreases the protein expression levels of NF-κB, p-IκBα and MAPKs in dorsal skin lesions

The expression of inflammatory cytokines is regulated by the transcription factor p65 NF-κB. PH treatment (1 and 100 mg/ml) inhibited the nuclear translocation of p65 NF-κB about 34.4 and 56.0%, respectively (P\<0.001). DEX group showed 50.4% reduction of NF-κB protein expression (P\<0.001). Also, p-IκBα expressions in PH1 (P\<0.05), PH100 (P\<0.001) and DEX (P\<0.001) groups were significantly decreased ([Fig. 5A](#f5-mmr-15-02-0649){ref-type="fig"}). Similarly, the protein expression levels of p-ERK1/2 (P\<0.001, [Fig. 5B](#f5-mmr-15-02-0649){ref-type="fig"}), p-p38 (P\<0.01, [Fig. 5C](#f5-mmr-15-02-0649){ref-type="fig"}) and p-JNK (P\<0.001, [Fig. 5D](#f5-mmr-15-02-0649){ref-type="fig"}) were dose-dependently downregulated following PH treatment.

Discussion
==========

The present study demonstrated an immunomodulatory effect of PH against AD progression and elucidated the underlying mechanism of action. The morphology of the DNCB-induced AD model revealed increased epidermal thickening and dermal infiltration of CD4^+^ T cells and mast cells, consistent with AD skin lesions. Repeated treatment with PH effectively improved the symptoms of AD by reducing hyperkeratosis and hyperplasia in the epidermis and dermis.

The high levels of IgE measured in AD are associated with the activation of underlying inflammatory cascades ([@b13-mmr-15-02-0649]). In addition, mast cells exhibit immunomodulatory activity via cross-talk with various biological mediators involved in IgE-mediated AD ([@b14-mmr-15-02-0649],[@b15-mmr-15-02-0649]). Therefore, the present study investigated whether topical treatment of PH affected the serum level of IgE and the infiltration of mast cells. The DNCB group expressed the greatest levels of IgE in serum and numbers of mast cells in skin. Topical application of 1 and 100 mg/ml PH suppressed serum IgE levels by 30.9 and 73.2%, respectively. The reduction of IgE concentrations is consistent with the suppression of mast cell infiltration into the dermis following PH treatment.

T cells are crucial for immune responses, and the dysregulation of the CD4^+^ T cell subset is an important aspect of AD pathophysiology ([@b16-mmr-15-02-0649]). A previous study determined that CD4^+^ T cells increased in numbers in the AD-like skin lesions in DNCB-induced mice model ([@b17-mmr-15-02-0649]). Accordingly, the elevation of CD4 expression in the dermis may suggest that Th1 and Th2 cells are involved ([@b4-mmr-15-02-0649]). The present study revealed that PH suppressed increases in CD4^+^ cell numbers, were assumed to be CD4^+^ T cells in the skin. Activated CD4^+^ T cells have two distinct subfamilies, Th1 cells and Th2 cells, classified by the cytokines they secrete. The topical treatment of PH significantly suppressed the expression levels of Th1-(IFN-γ) and Th2-(IL-4 and −6) specific cytokines. In addition, IFN-γ may contribute to the proliferation and differentiation of infiltrating macrophages, which may aggravate AD-like skin lesions ([@b18-mmr-15-02-0649]). The reduction of IFN-γ expression levels may be associated with the immunosuppressive effects of PH, via inhibition of macrophage recruitment to the site of inflammation. Th2 cells produce IL-4 and −6, and are associated with cell and membrane destruction in acute atopic dermatitis ([@b19-mmr-15-02-0649],[@b20-mmr-15-02-0649]). PH treatment decreased the increased expression levels of IL-4 and −6 induced by DNCB application.

The modulating effect of PH on Th1 and Th2 immune responses appears to have been demonstrated by the effects on serum IgE levels. In addition, overexpression of IL-8, TNF-α and IL-1β may be associated with a high number of infiltrated macrophages and basophils in the dermis ([@b21-mmr-15-02-0649]). Topical treatment with PH significantly reduced IL-8, TNF-α and IL-1β expression levels and these findings were more pronounced in the PH100 group.

NF-κB is critical for inflammatory cytokine transcriptional regulation and is important for immune responses. The activation of the NF-κB signaling pathway results in the phosphorylation and therefore degradation of IκB ([@b22-mmr-15-02-0649]). In the DNCB-induced mouse model of the present study, PH inhibited the phosphorylation of IκBα and the nuclear translocation of NF-κB. In addition, MAPKs represent a critical signaling cascade in immune responses, interacting with NF-κB to regulate inflammation ([@b23-mmr-15-02-0649],[@b24-mmr-15-02-0649]). In the present study, DNCB-induced phosphorylation of all three MAPKs was reduced by PH treatment. These results support the hypothesis that the inhibitory effects of PH on pro-inflammatory cytokine expression are due to suppression of the MAPK and NF-κB signaling pathways.

In conclusion, the results of the present study demonstrated a reduction in the pathological features of AD, including dorsal skin thickness, mast cell infiltration and release of IgE following treatment with PH, supporting the clinical potential of PH as an alternative therapeutic strategy for the management of AD. The inhibition of Th1 and Th2 inflammatory cytokines suggests that PH may exert anti-AD activity by regulating a series of immune pathological events, including the expression of NF-κB, p-IκBα and MAPKs. PH may therefore affect Th1/Th2 immune dysregulation, leading to the suppression of the features of AD.

The present study was supported by the National Research Foundation of Korea funded by the Korean government (grant no. NRF-2015R1A4A1042399).

![*Pseudostellaria heterophylla* treatment reduces dorsal skin thickness. (A) Histological assessment of the dorsal skin of each group following hematoxylin and eosin staining. Magnification, ×100; scale bar=200 µm. (B) Epidermal and (C) dermal thicknesses were quantified in 35 randomly selected fields per group. Data are presented as the mean ± standard deviation (n=5). ^\#\#\#^P\<0.001 vs. NOR; \*\*\*P\<0.001 and \*\*P\<0.01 vs. DNCB. NOR, vehicle-treated mice; DNCB, 2,4-dinitrochlorobenzene-treated mice; DEX, 2,4-dinitrochlorobenzene- and dexamethasone-treated mice; PH1, 2,4-dinitrochlorobenzene- and 1 mg/ml *Pseudostellaria heterophylla*-treated mice; PH100, 2,4-dinitrochlorobenzene- and 100 mg/ml *P*. *heterophylla*-treated mice.](MMR-15-02-0649-g00){#f1-mmr-15-02-0649}

![*Pseudostellaria heterophylla* decreases the number of mast cells in dorsal skin and serum IgE levels. (A) Mast cells were detected by toluidine blue staining. Magnification, ×100; scale bar=200 µm. (B) Infiltration of mast cells was quantified by counting the mast cells in the slides (n=5). (C) Serum levels of IgE were measured by ELISA. Data are presented as the mean ± standard deviation (n=5). ^\#\#\#^P\<0.001 vs. NOR; \*\*\*P\<0.001 and \*\*P\<0.01 vs. DNCB. NOR, vehicle-treated mice; DNCB, 2,4-dinitrochlorobenzene-treated mice; DEX, 2,4-dinitrochlorobenzene- and dexamethasone-treated mice; PH1, 2,4-dinitrochlorobenzene- and 1 mg/ml *Pseudostellaria heterophylla*-treated mice; PH100, 2,4-dinitrochlorobenzene- and 100 mg/ml *P*. *heterophylla*-treated mice; IgE, immunoglobulin E.](MMR-15-02-0649-g01){#f2-mmr-15-02-0649}

![*Pseudostellaria heterophylla* suppresses the infiltration of CD4^+^ T cells into dorsal skin. Representative images revealing CD4 staining, as detected by immunohistochemistry. Magnification, ×100; scale bar=200 µm. NOR, vehicle-treated mice; DNCB, 2,4-dinitrochlorobenzene-treated mice; DEX, 2,4-dinitrochlorobenzene- and dexamethasone-treated mice; PH1, 2,4-dinitrochlorobenzene- and 1 mg/ml *Pseudostellaria heterophylla*-treated mice; PH100, 2,4-dinitrochlorobenzene- and 100 mg/ml *P*. *heterophylla*-treated mice; CD, cluster of differentiation.](MMR-15-02-0649-g02){#f3-mmr-15-02-0649}

![*Pseudostellaria heterophylla* inhibits the mRNA expression levels of Th1, Th2 and pro-inflammatory cytokines in dorsal skin. (A) The expression of mRNA was quantified using reverse transcription-polymerase chain reaction. (B) IFN-γ, (C) IL-4, (D) IL-6, (E) IL-8, (F) TNF-α and (G) IL-1β mRNA expression levels were normalized to GAPDH. Data are presented as the mean ± standard deviation (n=5). ^\#\#\#^P\<0.001 vs. NOR; \*\*\*P\<0.001, \*\*P\<0.01 and \*P\<0.05 vs. DNCB. NOR, vehicle-treated mice; DNCB, 2,4-dinitrochlorobenzene-treated mice; DEX, 2,4-dinitrochlorobenzene- and dexamethasone-treated mice; PH1, 2,4-dinitrochlorobenzene- and 1 mg/ml *Pseudostellaria heterophylla*-treated mice; PH100, 2,4-dinitrochlorobenzene- and 100 mg/ml *P*. *heterophylla*-treated mice; Th, T helper; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.](MMR-15-02-0649-g03){#f4-mmr-15-02-0649}

![*Pseudostellaria heterophylla* decreases the protein expression levels of NF-κB, p-IκBα and MAPKs in dorsal skin lesions. (A) NF-κB protein expression levels in nuclear extracts and p-IκBα protein expression levels in cytosolic extracts. The protein expression levels of the MAPKs (B) p-ERK1/2, (C) p-p38 and (D) p-JNK were analyzed in whole extracts. Data are presented as the mean ± standard deviation (n=5). ^\#\#\#^P\<0.001 vs. NOR; \*\*\*P\<0.001, \*\*P\<0.01 and \*P\<0.05 vs. DNCB. NOR, vehicle-treated mice; DNCB, 2,4-dinitrochlorobenzene-treated mice; DEX, 2,4-dinitrochlorobenzene- and dexamethasone-treated mice; PH1, 2,4-dinitrochlorobenzene- and 1 mg/ml *Pseudostellaria heterophylla*-treated mice; PH100, 2,4-dinitrochlorobenzene- and 100 mg/ml *P*. *heterophylla*-treated mice; NF, nuclear factor; I, inhibitor; p, phosphorylated; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase.](MMR-15-02-0649-g04){#f5-mmr-15-02-0649}

###### 

Primer sequences used for reverse transcription polymerase chain reaction.

  Target gene               Direction   Sequence (5′-3′)             Amplicon size (bp)
  ------------------------- ----------- ---------------------------- --------------------
  Interferon-γ              Forward     AGCGGCTGACTGAACTCAGATTGTAG   330
                            Reverse     GTCACAGTTTTCAGCTGTATAGGG     
  Interleukin-4             Forward     ATGGGTCTCAACCCCCAGC          300
                            Reverse     GCTCTTTACGCTTTCCAGGAAGTC     
  Interleukin-6             Forward     ATCAACTCCTTCTCCACA AGCGC     628
                            Reverse     GAAGAGCCCTCAGGCTGGACTG       
  Interleukin-8             Forward     TGTGGGAGGCTGTGTTTGTA         200
                            Reverse     ACGAGACCAGGAGAAACAGG         
  Tumor necrosis factor-α   Forward     GGTGCAATGCAGAGCCTTCC         173
                            Reverse     CAGTGATGTAGCGACAGCCTGG       
  Interleukin-1β            Forward     CTCTAGACCATGCTACAGAC         291
                            Reverse     TGGAATCCAGGGGAAACACTG        
  GAPDH                     Forward     GGCATGGACTGTGGTCATGA         376
                            Reverse     TTCACCACCATGGAGAAGGC         
